alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 84 studies with an author at Université de Bordeaux (FR) (page 3 of 4) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

ESO Guideline on covert cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 55 out of 100. European stroke journal 2021-05-11

'Covert' cerebral small vessel disease (ccSVD) is common on neuroimaging in persons without overt neurological manifestations, and increases the risk of future stroke, cognitive impairment, dependency, and death. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Facets of language performance in early‐onset and late‐onset Alzheimer's disease dementia

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer s & Dementia 2025-09-01

Based on data from their first NACC visit with AD, there was considerable heterogeneity in language performance across people with EOAD and LOAD. 5 key findings →

Design: cross-sectional Participants: 1,189 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Immunity 2022-08-16

The apolipoprotein E4 (APOE4) allele is associated with an increased risk of Alzheimer disease and a decreased risk of glaucoma, but the underlying mechanisms remain poorly understood. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Statistics in medicine 2013-09-12

The area under the time-dependent ROC curve (AUC) may be used to quantify the ability of a marker to predict the onset of a clinical outcome in the future. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Annals of neurology 2014-02-18

α-Synuclein species contained in PD-derived LB are pathogenic and have the capacity to initiate a PD-like pathological process, including intracellular and presynaptic accumulations of pathological α-synuclein in different brain areas and slowly progressive axon-initiated dopaminergic nigrostriatal neurodegeneration. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association between herpes simplex virus infection and Alzheimer's disease biomarkers: analysis within the MAPT trial

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Scientific reports 2025-01-18

In vitro and animal studies have suggested that inoculation with herpes simplex virus 1 (HSV-1) can lead to amyloid deposits, hyperphosphorylation of tau, and/or neuronal loss. 4 key findings →

Participants: 58 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Proteogenomics in cerebrospinal fluid and plasma reveals new biological fingerprint of cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Nature Aging 2025-11-20

Cerebral small vessel disease (cSVD) is a leading cause of stroke and dementia with no specific treatment, of which molecular mechanisms remain poorly understood. 2 key findings →

Participants: 40,000 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Neurobiology of aging 2017-07-14

We performed whole-exome and whole-genome sequencing in 927 late-onset Alzheimer disease (LOAD) cases, 852 early-onset AD (EOAD) cases, and 1273 controls from France. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Healthcare Utilization Among Older Adults With Dementia in France: A Comparative Analysis of a Dementia Village and Traditional Nursing Homes

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Value in Health 2026-03-10

VLAHE residents had fewer hospitalizations and shorter stays (10.5 vs 15.2 days, P = .0004) than comparable NH residents, particularly for acute care. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Nature genetics 2026-09-14

Among the more than 90 identified genetic risk loci for late-onset Alzheimer's disease (AD) and related dementias, the apolipoprotein E (APOE) gene ɛ2/ɛ3/ɛ4 polymorphisms remain the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1-10 . 5 key findings →

Design: case-control Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Low circulating adropin concentrations predict increased risk of cognitive decline in community-dwelling older adults

✓ Peer-reviewed alzhub usefulness score 49 out of 100. GeroScience 2023-05-26

The secreted peptide adropin is highly expressed in human brain tissues and correlates with RNA and proteomic risk indicators for dementia. 2 key findings →

Participants: 452 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of the American Geriatrics Society 1992-11-01

The four IADL score could be incorporated into the screening procedure for dementia in elderly community dwellers. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Genetic contributions to Alzheimer’s disease and frontotemporal dementia in admixed Latin American populations

✓ Peer-reviewed alzhub usefulness score 48 out of 100. npj Dementia 2026-01-21

Latin America’s diverse genetic landscape provides a unique opportunity to study Alzheimer’s disease (AD) and frontotemporal dementia (FTD). 1 key finding →

Participants: 2,162 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Detecting amyloid and tau pathology in Parkinson’s disease, 4R-tauopathies and control subjects with plasma pTau217

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in Neurology 2025-08-15

Plasma pTau217 levels serve as a scalable, non-invasive marker of AD-pathology across Lewy body diseases, PSP/CBS, and MCI/CU populations. 2 key findings →

Participants: 18 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Exploring sex differences in the relationship between depressive symptoms and dementia incidence: prospective results from the PAQUID Study

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Geriatrics Society 2003-08-01

Ninety-seven men (incidence rate: 14.4/1,000) and 183 women (Incidence rate: 19.0/1,000) developed dementia during 8 years of follow-up. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The late stage of Parkinson's -results of a large multinational study on motor and non-motor complications

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Parkinsonism & related disorders 2020-05-21

These data suggest that current treatment of late stage parkinsonism in the community remains insufficiently effective to alleviate disabling symptoms in many patients. 3 key findings →

Participants: 692 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Molecular psychiatry 2018-08-14

The Alzheimer's Disease Sequencing Project (ADSP) undertook whole exome sequencing in 5,740 late-onset Alzheimer disease (AD) cases and 5,096 cognitively normal controls primarily of European ancestry (EA), among whom 218 cases and 177 controls were Caribbean Hispanic (CH). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed